Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results

Area of Science:

• Neurology
• Pediatrics
• Rehabilitation Medicine

Background:

• Cerebral palsy (CP) often involves spasticity, impacting motor function.
• Botulinum toxin type A is used to manage spasticity in CP.
• Evaluating functional benefits of botulinum toxin type A is crucial for treatment optimization.

Purpose of the Study:

• To assess the functional benefits of botulinum toxin type A injections in children with diparetic cerebral palsy.
• To evaluate changes in both simple clinical measures and complex motor functions.

Main Methods:

• An open-label, prospective study involving 14 children with cerebral palsy (mean age 3.9 years).
• Patients received Dysport (botulinum toxin type A) at 30 IU/kg.
• Evaluations included the Modified Ashworth Scale, Selective Motor Control, Passive Range of Movements, Physician Rating Scale, Clinical Global Impression, and Gross Motor Function Measure (GMFM).

Main Results:

• Statistically significant improvements (P < 0.05) were observed in simple measures and GMFM dimensions D and E at 1 and 3 months post-injection.
• Simple measure scores decreased after 3 months but remained above baseline.
• GMFM scores continued to increase, showing a 7.7% change at 3 months and 11.3% at 6 months in nine patients.

Conclusions:

• Botulinum toxin type A injections demonstrate a functional benefit in children with diparetic cerebral palsy.
• The study suggests persistent functional gains, especially in complex motor skills, with long-term treatment.
• Findings support the use of botulinum toxin type A for managing spasticity and improving function in cerebral palsy.